Vilanterol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vilanterol
Vilanterol.svg
Systematic (IUPAC) name
4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
Clinical data
Legal status
Identifiers
ATC code R03AK10 (+fluticasone)
R03AL03 (+umeclidinium)
PubChem CID 10184665
ChemSpider 8360167
ChEBI CHEBI:75037
Chemical data
Formula C24H33Cl2NO5 
Mol. mass 486.43 g/mol

Vilanterol (USAN) is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1] Vilanterol is not available on its own, but only in combination with fluticasone (Breo® in the US; Relvar Ellipta® in the UK).

References[edit]